PALO ALTO — Revance Therapeutics, Inc., a biotech company developing next-generation forms of Botox, has tapped a team from Cooley to smooth the path toward a projected $86 million initial public offering. Menlo Park–based attorneys from Davis Polk & Wardwell are advising underwriters.
Revance, which is headquartered in Newark, Calif., and was founded in 1999, develops new treatments using botulinum toxin for aesthetic and therapeutic purposes. The company expects to report Phase 3 clinical results for its lead product candidate, a topical gel that improves the appearance of crow’s feet wrinkles, this year. Other products are meant to address issues ranging from migraines to excessive sweating.
